Trials / Recruiting
RecruitingNCT06916702
A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 3031185 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3031185 in healthy male subjects following administration of multiple rising doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 3031185 | BI 3031185 |
| DRUG | Midazolam | Midazolam |
| DRUG | Placebo | Placebo matching BI 3031185 |
Timeline
- Start date
- 2025-04-07
- Primary completion
- 2026-11-02
- Completion
- 2026-11-02
- First posted
- 2025-04-08
- Last updated
- 2026-02-17
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT06916702. Inclusion in this directory is not an endorsement.